Director sold ~$228K of Arrowhead Pharmaceuticals
Scheduled in advanceTraded Apr 23, 2026 · Filed Apr 24, 2026
Arrowhead Pharmaceuticals's Chief Medical Officer sold $750K of Arrowhead Pharmaceuticals shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$750,000
Shares × reported transaction price
77 days after results of Feb 5, 2026, 14 days before results of May 7, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.8% | +0.4% | +3.4% |
| 30 days | +7.3% | +4.9% | +2.4% |
| 90 days | +16.2% | +3.3% | +12.9% |
Past results only. Not a forecast.
Director sold ~$228K of Arrowhead Pharmaceuticals
Scheduled in advanceCFO sold ~$225K of Arrowhead Pharmaceuticals
Scheduled in advanceCFO sold ~$82K of Arrowhead Pharmaceuticals
Scheduled in advance